Abstract
We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20+, B-cell, non-Hodgkin lymphoma (NHL). We now provide long-term follow-up data in responding patients based on International Workshop Response Criteria. Complete (CR), CR unconfirmed (CRu), and partial response (PR) rates were 29%, 22%, and 22%, respectively (overall response rate 73%, 51% in CR/CRu). Mean time to progression (TTP) and duration of response (DR) in responders were 12.6 months and 11.7 months, respectively. At the maximum tolerated dose (0.4 mCi/kg [14.8 MBq/kg]), TTP and DR in complete responders (CR/CRu) were 28.3 and 27.5 months, respectively. Nine patients (24% of responding patients) had a TTP of more than 3 years. Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4429-4431 |
| Number of pages | 3 |
| Journal | Blood |
| Volume | 103 |
| Issue number | 12 |
| DOIs | |
| State | Published - Jun 15 2004 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma : Long-term follow-up of a phase 1/2 study. / Gordon, Leo I.; Molina, Arturo; Witzig, Thomas Elmer; Emmanouilides, Christos; Raubtischek, Andrew; Darif, Mohamed; Schilder, Russell J.; Wiseman, Greg; White, Christine A.
In: Blood, Vol. 103, No. 12, 15.06.2004, p. 4429-4431.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma
T2 - Long-term follow-up of a phase 1/2 study
AU - Gordon, Leo I.
AU - Molina, Arturo
AU - Witzig, Thomas Elmer
AU - Emmanouilides, Christos
AU - Raubtischek, Andrew
AU - Darif, Mohamed
AU - Schilder, Russell J.
AU - Wiseman, Greg
AU - White, Christine A.
PY - 2004/6/15
Y1 - 2004/6/15
N2 - We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20+, B-cell, non-Hodgkin lymphoma (NHL). We now provide long-term follow-up data in responding patients based on International Workshop Response Criteria. Complete (CR), CR unconfirmed (CRu), and partial response (PR) rates were 29%, 22%, and 22%, respectively (overall response rate 73%, 51% in CR/CRu). Mean time to progression (TTP) and duration of response (DR) in responders were 12.6 months and 11.7 months, respectively. At the maximum tolerated dose (0.4 mCi/kg [14.8 MBq/kg]), TTP and DR in complete responders (CR/CRu) were 28.3 and 27.5 months, respectively. Nine patients (24% of responding patients) had a TTP of more than 3 years. Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma.
AB - We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20+, B-cell, non-Hodgkin lymphoma (NHL). We now provide long-term follow-up data in responding patients based on International Workshop Response Criteria. Complete (CR), CR unconfirmed (CRu), and partial response (PR) rates were 29%, 22%, and 22%, respectively (overall response rate 73%, 51% in CR/CRu). Mean time to progression (TTP) and duration of response (DR) in responders were 12.6 months and 11.7 months, respectively. At the maximum tolerated dose (0.4 mCi/kg [14.8 MBq/kg]), TTP and DR in complete responders (CR/CRu) were 28.3 and 27.5 months, respectively. Nine patients (24% of responding patients) had a TTP of more than 3 years. Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma.
UR - http://www.scopus.com/inward/record.url?scp=2942595713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2942595713&partnerID=8YFLogxK
U2 - 10.1182/blood-2003-11-3883
DO - 10.1182/blood-2003-11-3883
M3 - Article
C2 - 15016644
AN - SCOPUS:2942595713
VL - 103
SP - 4429
EP - 4431
JO - Blood
JF - Blood
SN - 0006-4971
IS - 12
ER -